Search research articles
Contact Us
Filters
Showing results (271-280 of 441) with videos related to
Page
of 45
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver
|
June 10, 2011
Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data
David Kershenobich, Homie A Razavi, Curtis L Cooper, et al.
Journal of Hepatology
|
November 10, 2012
Clinical management of drug-drug interactions in HCV therapy: challenges and solutions
David Burger, David Back, Peter Buggisch, et al.
Cell Reports
|
December 17, 2025
In vivo efficacy of combined human broadly neutralizing antibodies against hepatitis B virus
Maxime Beretta, Ariel Mechaly, Cyril Planchais, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
February 8, 2014
Prevalence of renal abnormalities in chronic HBV infection: the HARPE study
Sabine Amet, Jean-Pierre Bronowicki, Dominique Thabut, et al.
The Lancet. Infectious Diseases
|
June 18, 2013
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial
Mark Sulkowski, Stanislas Pol, Josep Mallolas, et al.
Plos One
|
December 31, 2008
Symptomatic acute hepatitis C in Egypt: diagnosis, spontaneous viral clearance, and delayed treatment with 12 weeks of pegylated interferon alfa-2a
Noha Sharaf Eldin, Soheir Ismail, Hala Mansour, et al.
Antiviral Therapy
|
August 24, 2007
Serum alpha-foetoprotein level predicts treatment outcome in chronic hepatitis C
Sylvia Males, Rita Raafat Gad, Gamal Esmat, et al.
BMC Global and Public Health
|
July 2, 2025
Mortality risk in migrant and non-migrant individuals with chronic hepatitis B virus infection: a French hospital-based cohort study (ANRS CO22 HEPATHER)
Marta Lotto, Clémence Ramier, Fabrice Carrat, et al.
JAMA
|
December 16, 2004
Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial
Fabrice Carrat, Firouzé Bani-Sadr, Stanislas Pol, et al.
Hepatology (Baltimore, Md.)
|
January 30, 2016
Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)
Vincent Leroy, Peter Angus, Jean-Pierre Bronowicki, et al.
Page
of 45
Search research articles
Search
Showing results (271-280 of 441) with videos related to
Sort By:
Page
of 45
Liver International : Official Journal of the International Association for the Study of the Liver
|
June 10, 2011
Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data
David Kershenobich, Homie A Razavi, Curtis L Cooper, et al.
Journal of Hepatology
|
November 10, 2012
Clinical management of drug-drug interactions in HCV therapy: challenges and solutions
David Burger, David Back, Peter Buggisch, et al.
Cell Reports
|
December 17, 2025
In vivo efficacy of combined human broadly neutralizing antibodies against hepatitis B virus
Maxime Beretta, Ariel Mechaly, Cyril Planchais, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
February 8, 2014
Prevalence of renal abnormalities in chronic HBV infection: the HARPE study
Sabine Amet, Jean-Pierre Bronowicki, Dominique Thabut, et al.
The Lancet. Infectious Diseases
|
June 18, 2013
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial
Mark Sulkowski, Stanislas Pol, Josep Mallolas, et al.
Plos One
|
December 31, 2008
Symptomatic acute hepatitis C in Egypt: diagnosis, spontaneous viral clearance, and delayed treatment with 12 weeks of pegylated interferon alfa-2a
Noha Sharaf Eldin, Soheir Ismail, Hala Mansour, et al.
Antiviral Therapy
|
August 24, 2007
Serum alpha-foetoprotein level predicts treatment outcome in chronic hepatitis C
Sylvia Males, Rita Raafat Gad, Gamal Esmat, et al.
BMC Global and Public Health
|
July 2, 2025
Mortality risk in migrant and non-migrant individuals with chronic hepatitis B virus infection: a French hospital-based cohort study (ANRS CO22 HEPATHER)
Marta Lotto, Clémence Ramier, Fabrice Carrat, et al.
JAMA
|
December 16, 2004
Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial
Fabrice Carrat, Firouzé Bani-Sadr, Stanislas Pol, et al.
Hepatology (Baltimore, Md.)
|
January 30, 2016
Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)
Vincent Leroy, Peter Angus, Jean-Pierre Bronowicki, et al.
Page
of 45